BioNano (BNGO) Stock
Key stats
- Market cap
- $16.77M
- Price / Earnings ratio
- -0.4x
- EPS (TTM)
- -$3.02
- Volume
- Loading
- 52-week high
- $2.23
- 52-week low
- $1.00
- EPS vs analyst estimate
- +25.4%Q3 FY25 · -$1.59 vs -$2.13
Source: third-party data provider, as of November 5, 2026
EPS estimate: analyst consensus
Compare with BNGO
Recent news
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?
BNGO
Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors
Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors
BNGO
Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
BNGO
Despite Fast-paced Momentum, Bionano Genomics (BNGO) Is Still a Bargain Stock
Despite Fast-paced Momentum, Bionano Genomics (BNGO) Is Still a Bargain Stock
BNGOTechnical indicators
- RSI 14
- 39.96
- MACD 12/26/9
- -0.07
- EMA 9 of MACD
- -0.07
- MACD histogram
- -0.00
- SMA 50
- $1.37
- Price below SMA 50
- EMA 50
- $1.31
- Price below EMA 50
- SMA 200
- $1.24
- Price below SMA 200
- EMA 200
- $1.32
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 4, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.77 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?
BNGOWhy Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors
Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors
BNGOBionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
BNGODespite Fast-paced Momentum, Bionano Genomics (BNGO) Is Still a Bargain Stock
Despite Fast-paced Momentum, Bionano Genomics (BNGO) Is Still a Bargain Stock
BNGO
Bionano Genomics (BNGO) Is Attractively Priced Despite Fast-paced Momentum
Bionano Genomics (BNGO) Is Attractively Priced Despite Fast-paced Momentum
BNGO
Bionano Genomics Retail Mood Turns ‘Extremely Bearish’ Amid Revenue Guidance Shortfall
Bionano Genomics Retail Mood Turns ‘Extremely Bearish’ Amid Revenue Guidance Shortfall
BNGO
Bears are Losing Control Over Bionano Genomics (BNGO), Here's Why It's a 'Buy' Now
Bears are Losing Control Over Bionano Genomics (BNGO), Here's Why It's a 'Buy' Now
BNGO
Bionano Genomics (BNGO) Upgraded to Buy: Here's Why
Bionano Genomics (BNGO) Upgraded to Buy: Here's Why
BNGO
3 Sorry Healthcare Stocks to Sell in May While You Still Can
3 Sorry Healthcare Stocks to Sell in May While You Still Can
BNGO
The 3 Best Healthcare Stocks to Buy in May 2024
The 3 Best Healthcare Stocks to Buy in May 2024
BNGOAbout BioNano
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Albert A. Luderer Ph.D. | Chairman, Interim CEO, Interim President & Interim Principal Financial Officer | 1949 |
| Mr. Mark Oldakowski | Chief Operating Officer | 1974 |
| Dr. Alex Hastie Ph.D. | Chief Scientific Officer | — |
| Mr. Jonathan Dixon J.D. | Chief Legal Officer & Corporate Secretary | 1975 |
| Mr. Cory Kreeck | Chief People Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 5, 2026
Technical indicators
- RSI 14
- 39.96
- MACD 12/26/9
- -0.07
- EMA 9 of MACD
- -0.07
- MACD histogram
- -0.00
- SMA 50
- $1.37
- Price below SMA 50
- EMA 50
- $1.31
- Price below EMA 50
- SMA 200
- $1.24
- Price below SMA 200
- EMA 200
- $1.32
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 4, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -28.0 | -19.2 | ||||||||||
| 2022 | -31.3 | -8.5 | +19.4 | -39.0 | +0.0 | -12.1 | +38.8 | +34.1 | -25.6 | +30.0 | -15.5 | -26.3 |
| 2023 | +25.7 | -27.6 | -14.6 | -36.9 | +3.2 | -16.7 | -7.5 | -36.5 | -21.3 | -52.9 | +19.5 | +13.9 |
| 2024 | -41.0 | +9.6 | -11.2 | -17.5 | +1.0 | -27.1 | -3.2 | -16.5 | -2.4 | -31.8 | -9.3 | +13.4 |
| 2025 | -66.1 | -21.5 | -30.3 | +28.7 | -8.3 | -10.9 | -8.8 | +27.8 | -58.2 | +3.4 | +7.6 | -11.0 |
| 2026 | -18.2 | -9.4 | +2.6 | -2.5 | +5.1 | -9.6 | -8.5 | +8.9 | +27.9 | -26.8 | +2.6 |
Corporate actions
Upcoming
No upcoming corporate actions for BNGO
